top of page
![](https://static.wixstatic.com/media/ad420a_f98d68876fc145f595d999cec41dda12~mv2.jpg/v1/fill/w_100,h_56,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/ad420a_f98d68876fc145f595d999cec41dda12~mv2.jpg)
21/10/20
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor
Piacentini D, Lanzafame M, Rizzardo S, Chiesi S, Lattuada E, Mehrabi S, Zamboni G, Mazzi R, Tacconelli E, Vento S
Abstract: Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral drugs with high virologic efficacy and excellent tolerability. Recent evidence showed a possible link of dolutegravir-based regimens with weight gain, and a relationship between raltegravir use and changes in adipose tissue density and metabolic abnormalities, with an increased cardiovascular risk, has been suggested. We describe a case where dolutegravir monotherapy led to a decrease in adipose tissue density.
Keywords: HIV; adipose tissue density; dolutegravir; integrase strand transfer inhibitor; weight gain.
bottom of page